Model study moduleΒΆ
Tumors from PDX often undergo comprehensive genomic characterization and/or treatment in controlled dosing studies to define therapeutic response and resistance. PDX-MI includes desirable fields in the reporting of these studies that supplement existing guidelines for reporting on in vivo biomedical research ( Meehan et al., 2017).
| Field | Rec | Example | PDXNet |
|---|---|---|---|
| Study name or identifier | PDX-123P3 Pertuzmab/Trastuzumab | Needs to be unique to attach files | |
| Treatment | D | pertuzumab in combination with trastuzumab; CHEMBL2007641 | List of 1 or more generic drugs |
| Treatment protocol | D | trastuzumab (30 mg/kg loading dose, 15 mg/kg weekly); | Additional module to capture Drug,Dose,Route,Frequency |
| Treatment Response | D | RECIST Term | |
| Passage | D | P2 | Integer |
| Metastasis | D | Yes | Yes or No |
| Metastasized to | D | Liver | Uberon |
| Metastasis in passage | D | P3 | Integer |
| Lag time/doubling time | D | 48h | separate elements |
Table 2.5. Model study module. Rec: Recommendation; E: essential; D:desirable.
1. Study Name or identifier (if not available could be model + passage + treatment) A way to uniquly identify the study. Human readable or unique ID
2. Treatment List of treatment(s) as generic terms for medications.
3. Treatment protocol For each treatment drug provide drug name, dosage, route and frequency.
4. Treatment response complete response, partial response, stable disease, progressive disease.
5 Model Passage Passage(s) of models used in study. Assumption is P0 modles have tissue directly from patient. P1 is engrafted with tissue from P0 etc.
Tumor OMICS: This was removed. It will be populated based on types of files uploaded for Study/Model.
6,7,8 Development of metastases in strain We will code this as Yes/no; site as uberon; passage as enumeration
9. Lag time/doubling time of tumor We will code this as the number of hours.